Recombinant interferon-alpha-2C in laryngeal papillomatosis: preliminary results of a prospective multicentre trial.
A preparation of interferon-alpha 2C of high purity formed by recombinant DNA technology was used as adjuvant therapy following removal of laryngeal papillomas by cauterization or laser vaporization. Preliminary data on 20 patients are reported and include 11 complete and 7 partial responses. Side-effects included initial temperature elevation, but this subsided and other side-effects were uncommon. No antibodies to the interferon preparation were found in any of the patients.
D002986:Clinical Trials as Topic; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010212:Papilloma / Q000628:therapy*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins